Comparison
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870 vs 3 Methylglutaconic Aciduria Type 3 C0574084
Clinical comparison between 46 XY Disorder OF Sex Development Due TO Impaired Androgen Production and 3 Methylglutaconic Aciduria Type 3 for differential diagnosis and treatment planning.
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
A disorder where androgen production is impaired in 46,XY individuals. Results in undervirilization and atypical genital development. Treated with hormone replacement and supportive care.
3 Methylglutaconic Aciduria Type 3 C0574084
A genetic metabolic disorder that primarily affects the nervous system, often causing vision problems, movement difficulties, and cognitive challenges. Treatment involves supportive therapies and regular monitoring.
6 comparison axes
Onset
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
0-0
3 Methylglutaconic Aciduria Type 3 C0574084
1-10
Onset patterns differ
Severity
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
severe
3 Methylglutaconic Aciduria Type 3 C0574084
moderate
Different severity levels
Chronic
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
Chronic
3 Methylglutaconic Aciduria Type 3 C0574084
Chronic
Differing course
Communicable
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
No
3 Methylglutaconic Aciduria Type 3 C0574084
No
Different transmission
Body System
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
reproductive
3 Methylglutaconic Aciduria Type 3 C0574084
metabolic
Same/different system
Category
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
endocrine
3 Methylglutaconic Aciduria Type 3 C0574084
metabolic
Different category
Bottom line
46-xy-disorder-of-sex-development-due-to-impaired-androgen-production-C5679870 and 3-methylglutaconic-aciduria-type-3-C0574084 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870 | 3 Methylglutaconic Aciduria Type 3 C0574084 | Discriminating power |
|---|---|---|---|
| Genital development | Congenital undervirilization or atypical genitalia may occur in 46,XY individuals. | Atypical genital development is not the defining feature described. | High |
| Vision and movement | Not primarily described as an optic or movement disorder. | Vision problems and movement difficulties may emerge during childhood. | High |
| Metabolic findings | No characteristic organic aciduria is supplied. | 3-methylglutaconic acid elevation may support, but not alone confirm, the diagnosis. | Moderate |
When to favor each condition
Choose 46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870 when
Newborn with 46,XY karyotype and atypical genitalia
This pattern aligns with impaired androgen production rather than the described neurometabolic disorder.
High
Endocrine testing suggests reduced androgen production or effect
Supports the supplied mechanism, but the exact cause requires specialist confirmation.
Moderate
No optic, movement, or organic-acid abnormality is found
Makes type 3 less likely, although absence does not establish the left diagnosis.
Moderate
Choose 3 Methylglutaconic Aciduria Type 3 C0574084 when
Child develops vision loss with movement difficulty
This matches the described neurologic pattern more than an androgen-production disorder.
Moderate
Urine organic acids suggest 3-methylglutaconic aciduria
Supports metabolic evaluation; genetic confirmation is still required.
Moderate
OPA3-related genetic findings are identified
Genetic evidence distinguishes type 3 from the endocrine condition.
High
How key tests differ
| Test | 46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870 | 3 Methylglutaconic Aciduria Type 3 C0574084 | Interpretation |
|---|---|---|---|
| Karyotype and genital assessment | 46,XY with undervirilization may be present. | Karyotype is not diagnostic. | Genital phenotype guides endocrine evaluation but is not a complete diagnosis. |
| Androgen pathway studies | Androgen production or effect may be reduced; no cutoff is supplied. | Not expected to explain the core disorder. | Results require pediatric endocrine interpretation. |
| Urine organic acids and OPA3 testing | No defining organic-acid pattern is supplied. | 3-methylglutaconic acid elevation and OPA3 variants may support diagnosis. | Avoid numeric cutoffs; confirm in a specialist laboratory. |
Prognosis comparison
46 Xy Disorder Of Sex Development Due To Impaired Androgen Production C5679870
- Outcome
- Chronic endocrine condition with variable, unquantified long-term outcome.
- Factors
- Specific cause, degree of undervirilization, and timing of specialist care.
3 Methylglutaconic Aciduria Type 3 C0574084
- Outcome
- Chronic neurometabolic condition that may affect vision, movement, and cognition.
- Factors
- Neurologic severity and availability of supportive services.
Time frame: From birth or childhood across life; exact progression is not established.
This comparison does not establish mortality or a uniform prognosis.
Complications comparison
| Complication | Presentation |
|---|---|
| Sex development and fertility | Undervirilization and possible fertility implications may occur. Not described as the primary complication. Counseling should be individualized; outcomes are not established here. |
| Vision and motor function | Not characteristic based on the supplied description. Vision and movement problems may limit function. Monitoring and supportive therapy are described, not curative treatment. |
| Cognition and development | Not described as the core feature. Cognitive challenges may occur. Developmental support may be considered after clinician assessment. |
Patient education highlights
- HighDifferent conditions
One concerns androgen-related sex development; the other is a metabolic disorder affecting the nervous system.
- HighSpecialist confirmation
An abnormal test is not itself a diagnosis and should be interpreted by an appropriate clinician.
- MediumSupportive care
Care may include hormone management or neurologic support; doses and outcomes are not established here.